Pharmsynthez, Kevelt, Xenetic deal

Xenetic will purchase worldwide rights to develop and commercialize Virexxa from Kevelt and Pharmsynthez for 111.5 million shares of Xenetic, valued at $93.7 million based on Xenetic close of $0.84 o...